These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
304 related articles for article (PubMed ID: 25646029)
21. Two-year results of intravitreal ranibizumab for polypoidal choroidal vasculopathy with recurrent or residual exudation. Saito M; Iida T; Kano M; Itagaki K Eye (Lond); 2013 Aug; 27(8):931-9. PubMed ID: 23743532 [TBL] [Abstract][Full Text] [Related]
22. Photodynamic therapy, ranibizumab, and ranibizumab with photodynamic therapy for the treatment of polypoidal choroidal vasculopathy. Rouvas AA; Papakostas TD; Ntouraki A; Douvali M; Vergados I; Ladas ID Retina; 2011 Mar; 31(3):464-74. PubMed ID: 20948458 [TBL] [Abstract][Full Text] [Related]
23. Intravitreal ranibizumab combined with verteporfin photodynamic therapy for treating polypoidal choroidal vasculopathy. Lee YH; Lee EK; Shin KS; Lee KM; Kim JY Retina; 2011; 31(7):1287-93. PubMed ID: 21386762 [TBL] [Abstract][Full Text] [Related]
24. Photodynamic therapy for polypoidal choroidal vasculopathy. Nowak-Sliwinska P; van den Bergh H; Sickenberg M; Koh AH Prog Retin Eye Res; 2013 Nov; 37():182-99. PubMed ID: 24140257 [TBL] [Abstract][Full Text] [Related]
26. Improvement of angiographic findings of polypoidal choroidal vasculopathy after intravitreal injection of ranibizumab monthly for 3 months. Hikichi T; Ohtsuka H; Higuchi M; Matsushita T; Ariga H; Kosaka S; Matsushita R; Takami K Am J Ophthalmol; 2010 Nov; 150(5):674-682.e1. PubMed ID: 20691424 [TBL] [Abstract][Full Text] [Related]
27. Argon laser with and without anti-vascular endothelial growth factor therapy for extrafoveal polypoidal choroidal vasculopathy. Gemmy Cheung CM; Yeo I; Li X; Mathur R; Lee SY; Chan CM; Wong D; Wong TY Am J Ophthalmol; 2013 Feb; 155(2):295-304.e1. PubMed ID: 23111181 [TBL] [Abstract][Full Text] [Related]
28. Intravitreal bevacizumab and ranibizumab injections for patients with polypoidal choroidal vasculopathy. Cho HJ; Kim JW; Lee DW; Cho SW; Kim CG Eye (Lond); 2012 Mar; 26(3):426-33. PubMed ID: 22173075 [TBL] [Abstract][Full Text] [Related]
29. Polypoidal choroidal vasculopathy: evidence-based guidelines for clinical diagnosis and treatment. Koh AH; ; Chen LJ; Chen SJ; Chen Y; Giridhar A; Iida T; Kim H; Yuk Yau Lai T; Lee WK; Li X; Han Lim T; Ruamviboonsuk P; Sharma T; Tang S; Yuzawa M Retina; 2013 Apr; 33(4):686-716. PubMed ID: 23455233 [TBL] [Abstract][Full Text] [Related]
30. Visual Outcome and Fluid Changes Between Eyes With Polypoidal Choroidal Vasculopathy Receiving Biosimilar CKD-701 or Reference Ranibizumab Therapy: A Post Hoc Analysis of a Phase 3 Randomized Clinical Trial. Nam KT; Yun C; Lee YJ; Choi M; Kang D; Oh J Curr Eye Res; 2024 Jun; 49(6):663-670. PubMed ID: 38450631 [TBL] [Abstract][Full Text] [Related]
31. Comparison of the Effectiveness and Prognostic Factors of Intravitreal Ranibizumab between Typical Neovascular Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy over 24 Months of Follow-Up. Matsumiya W; Honda S; Otsuka K; Miki A; Nagai T; Imai H; Kusuhara S; Nakamura M Ophthalmologica; 2015; 234(1):33-9. PubMed ID: 26112059 [TBL] [Abstract][Full Text] [Related]
32. Comparisons of outcomes with different intervals between adjunctive ranibizumab and photodynamic therapy for polypoidal choroidal vasculopathy. Sato T; Kishi S; Matsumoto H; Mukai R Am J Ophthalmol; 2013 Jul; 156(1):95-105.e1. PubMed ID: 23628354 [TBL] [Abstract][Full Text] [Related]